We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Carbapenem-Resistant Enterobacteriaceae Pose Triple Threat

By LabMedica International staff writers
Posted on 20 Mar 2013
Carbapenem-resistant Enterobacteriaceae (CRE) are an increasing and deadly threat in healthcare facilities in the United States of America. More...


Enterobacteriaceae are a large family of gram-negative bacilli that normally live in the human gastrointestinal tract, and are a common cause of both community- and healthcare-acquired infections.

The US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) has now issued an early warning, while the resistant infection is so far limited to inpatient facilities. Although resistance to broad-spectrum antibiotics has been seen for several decades, resistance to the carbapenem antimicrobial class is recent and appears to be spreading. During the first six months of 2012, among the 3,918 US acute-care hospitals performing surveillance for either catheter-associated urinary tract infections (CAUTI) or central-line-associated bloodstream infections (CLABSI) in any part of their hospital, 181 (4.6%) reported one or more infections with CRE, 145 in short-stay hospitals and 36 in long-term acute-care hospitals.

During the 5-month Emerging Infections Program (EIP) project pilots, 72 CRE were identified from 64 patients; 56 patients had 1 positive culture; 8 had 2. Fifty-nine came from the Atlanta metropolitan area, with 10 in the Minneapolis-St. Paul area and 3 from Portland, Oregon. There were 49 CRE identified as Klebsiella species, 14 as Enterobacter species and nine were Escherichia coli. The most common source was urine at 89%, with 10% in blood samples.

Thomas Frieden, MD, MPH, the CDC director, called CRE "nightmare bacteria" that post a "triple threat," because the organisms are resistant to nearly all antibiotics, they kill up to half of those infected, and they are capable of spreading their resistance to other bacteria. He advised that hospitals, nursing homes, and long-term care institutions adopt the recommendations issued previously in a CRE prevention toolkit.

Hospitals that have adopted the toolkit's recommendations have seen dramatic reductions in CRE infections. It advises measures such as requesting information about CRE-infected patients from laboratories; enforcing standard infection control and contact precautions; grouping CRE-infection inpatients together, using dedicated staff and equipment if possible; and prudent antimicrobial use. The report was published on March 8, 2013, in the journal Morbidity and Mortality Weekly Report.

Related Links:
US Centers for Disease Control and Prevention



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.